secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001437749-23-022895
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q2 2023 net loss widens to $5.93M ($0.22/sh); cash at $17.8M
-------------------------------------------------------------------

- Net loss for Q2 2023 was $5.93M ($0.22/sh) vs $2.24M ($0.18/sh) in Q2 2022.
- R&D expenses jumped to $4.72M from $1.31M YoY, driven by clinical trial and manufacturing costs.
- Cash and equivalents totaled $17.8M at June 30, 2023, down from $27.6M at Dec 31, 2022.
- Initiated Phase 2 trial of GEO-CM04S1 in CLL patients; Gedeptin Phase 1/2 interim data showed no DLTs.
- Expanded GEO-CM04S1 rights to include Mpox and smallpox; partnered with ABL for cGMP manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/0001437749-23-022895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/govx20230809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-022895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer